Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib plus Thalidomide in EGFR-mutant NSCLC
NCT03341494Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Apr 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thalidomide in non-small cell lung cancer (NSCLC), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
thalidomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03341494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341494.